NextCure, Inc.
NXTCHealthcare|Biotechnology|US
$5.33
+0.21 (+4.10%)
DCF Value
$6.71
Tangible Book / Share
$2.29
Cash / Share
$3.78
Clinical Trials (9)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT04699123 The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer | Advanced Non-small Cell Lung Cancer | P2 | Active | 159 | Open-label | NC318 800 mg, NC318 400 mg, Pembrolizumab |
| NCT06941857 NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer | Pancreatic Cancer | P2 | Recruiting | 20 | Open-label | Oxaliplatin, Irinotecan, Folinic Acid, 5-Fluorouracil (5-FU), NC410, Nivolumab, Ipilimumab |
| NCT06792552 A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors | Advanced Solid Tumors, Platinum Resistant Ovarian Cancer | P1 | Recruiting | 738 | RCT, Open-label | SIM0505 for injection, SIM0505 for injection |
| NCT04430933 A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic NSCLC | Advanced or Metastatic Solid Tumors, Non-Small Cell Lung Cancer | P1P2 | Withdrawn | — | Open-label | NC318, Pemetrexed/Carboplatin, Nab paclitaxel/Carboplatin, Docetaxel |
| NCT05572684 A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors | Advanced or Metastatic Solid Tumors, Microsatellite Instability Low | P1P2 | Terminated | 97 | Open-label | NC410, pembrolizumab |
| NCT04408599 A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors | Advanced or Metastatic Solid Tumors, Ovarian Cancer | P1P2 | Terminated | 46 | Open-label | NC410 |
| NCT03665285 A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors | Advanced or Metastatic Solid Tumors, Lung Cancer | P1P2 | Completed | 109 | Open-label | NC318 |
| NCT04875806 A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors | Advanced or Metastatic Solid Tumors, Ovarian Cancer | P1P2 | Terminated | 40 | Open-label | NC762 |
| NCT05787496 A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms | Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory Chronic Myelomonocytic Leukemia | P1 | Terminated | 28 | Open-label | NC525 |